21st Feb 2008 18:03
GlaxoSmithKline PLC21 February 2008 Notification of Transactions of Directors and Persons Discharging Managerial Responsibility Vesting of awards made under GlaxoSmithKline's share plans in 2004 This notification, prepared in accordance with Disclosure and Transparency Rule3.1.4R(1)(a), sets out the vesting of share awards made in 2004, under theGlaxoSmithKline Performance Share Plan. Performance Share Plan The three-year performance period for the GlaxoSmithKline Performance Share Plan(PSP) awards made in 2004, which commenced on 1 January 2005, came to an end on31 December 2007. The Remuneration Committee of the Board of GlaxoSmithKline plc (GSK) consideredthe performance achieved in respect of the PSP awards and determined that thePSP awards granted in 2004 vested as set out in the table below. The vesting ofthese awards was subject to the Company's relative Total Shareholder Return(TSR) performance for the individuals who were Executive Directors or CorporateExecutive Team (CET) members at the time the awards were made. For otherparticipants, the vesting of the awards was subject in part to TSR and in partto the Company's Earnings per Share (EPS) growth over the performance period. The following Executive Directors and CET members, who are all PersonsDischarging Managerial Responsibility (PDMRs), have received the following finalawards in respect of the awards made in 2004. The unvested balance of each awardhas lapsed. Number of Shares/ADSs vesting Shares ADSsDr JP Garnier* 86,327Mr A P Witty* 33,272Mr R M Bondy 33,272Mr J M Clarke 20,687Mr M Dunoyer 12,531Mr E J Gray 9,177Mr J S Heslop* 6,698Mr D Learmouth 4,332Dr M Slaoui* 9,177Dr R G Greig** 10,791Mr W C Louv 4,056Mr D J Phelan 16,618Mr D Pulman 10,791Mr D M Stout 31,941Mr C Viehbacher* 16,618 * denotes an Executive Director ** deferred until retirement Share Option Plan The three-year performance period for the GlaxoSmithKline Share Option Plan(SOP) awards made to appointed CET members in 2004, at an option price of £11.23(or US$43.730 in the case of ADSs), which commenced on 1 January 2005, came toan end on 31 December 2007. The performance conditions for this grant were met.The Remuneration Committee of the Board of GSK therefore confirmed that theywere exercisable in full. Number of Shares/ADSs exercisable Shares ADSsDr JP Garnier* 460,000Mr A P Witty* 177,500Mr R M Bondy 177,500Mr M Dunoyer 70,000Mr J S Heslop* 62,250Dr R G Greig 57,500Mr D J Phelan 88,750Mr D Pulman 57,500Mr D M Stout 170,000Mr C Viehbacher* 88,750 * denotes an Executive Director The Company, Directors, and Persons Discharging Managerial Responsibility wereadvised of these transactions on 21 February 2008. S M BicknellCompany Secretary 21 February 2008 Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 Alice Hunt (020) 8047 5502 Gwenan White (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline